Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout

Side effects have led Vertex Pharmaceuticals to stop work on another Phase II drug candidate to treat a rare genetic disease called alpha-1 antitrypsin defiency, or AATD, the biotech disclosed Monday in its third-quarter earnings report.

Vertex is discontinuing research on the small molecule called VX-864 because of “non-serious rash events in some patients,” according to a press release. About three years ago, Vertex abandoned another AATD program, called VX-814, that made it to Phase II after seeing signs of liver damage. Vertex’s stock price moved down about 2% to $379 after markets closed Monday.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。